首页|期刊导航|河北中医|参附救心汤对慢性心力衰竭合并缓慢型心律失常患者心室重构、Th17/Treg平衡的影响

参附救心汤对慢性心力衰竭合并缓慢型心律失常患者心室重构、Th17/Treg平衡的影响OA

Effects of Shenfu Jiuxin Decoction on ventricular remodeling and Th17/Treg balance in patients with chronic heart failure complicated by bradyarrhythmia

中文摘要英文摘要

目的 观察参附救心汤对慢性心力衰竭(CHF)合并缓慢型心律失常(BA)患者心室重构、辅助性 T 细胞17(Th17)/调节性 T 细胞(Treg)平衡的影响.方法 选取 2021 年 9 月至 2024 年 4 月陕西中医药大学第二附属医院心血管内科收治的 122 例 CHF 合并 BA 患者为研究对象,采用随机数字表法分为对照组(n=61)和治疗组(n=61).对照组给予西医常规治疗,治疗组在对照组基础上给予参附救心汤治疗.比较 2 组治疗前后心功能指标[左室射血分数(LVEF)、N 末端 B 型钠尿肽原(NT-proBNP)、6 分钟步行试验(6MWT)]、心室重构指标[左室后壁厚度(LVPWT)、室间隔厚度(IVST)、左心室质量指数(LVMI)]、心电图参数[心率(HR)、QT 间期、QT 离散度(QTd)]及 Th17/Treg,对比 2 组临床疗效及不良反应.结果 与治疗前相比,治疗后 2 组 LVEF、6MWT 距离、Treg 均升高(P<0.05),且治疗组较对照组更高(P<0.05).与治疗前相比,治疗后 2 组 NT-proBNP、LVPWT、IVST、LVMI、HR、QT 间期、QTd、Th17、Th17/Treg 均降低(P<0.05),且治疗组较对照组更低(P<0.05).治疗组总有效率为 91.80%(56/61),对照组为 77.05%(47/61),治疗组总有效率高于对照组(P<0.05).2 组不良反应发生率比较差异无统计学意义(P>0.752).结论 参附救心汤治疗 CHF合并 BA 疗效显著,能改善患者心功能及心室重构,恢复机体免疫功能,安全性良好.

Objective To observe the effects of Shenfu Jiuxin Decoction on ventricular remodeling and the balance of helper T cell 17(Th17)/regulatory T cell(Treg)in patients with chronic heart failure(CHF)complicated by bradyarrhythmia(BA).Methods A total of 122 patients with CHF complicated by BA admitted to the Department of Cardiovascular Medicine of the Second Affiliated Hospital of Shaanxi University of Chinese Medicine from September 2021 to April 2024 were enrolled and randomly assigned,using a random number table,to a control group(n=61)and a treatment group(n=61).The control group received conventional Western medical treatment,and the treatment group received Shenfu Jiuxin Decoction in addition to the treatment given to the control group.Before and after treatment,the two groups were compared in terms of cardiac function indicators(left ventricular ejection fraction[LVEF],N-terminal pro-brain natriuretic peptide[NT-proBNP],6-minute walk test[6MWT]),ventricular remodeling indicators(left ventricular posterior wall thickness[LVPWT],interventricular septal thickness[IVST],left ventricular mass index[LVMI]),electrocardiographic parameters(heart rate[HR],QT interval,QT dispersion[QTd]),and Th17/Treg balance.Clinical efficacy and adverse reactions were also compared between the two groups.Results Compared with baseline,LVEF,6MWT distance,and Treg increased after treatment in both groups(P<0.05),and were higher in the treatment group than in the control group(P<0.05).Compared with baseline,NT-proBNP,LVPWT,IVST,LVMI,HR,QT interval,QTd,Th17,and Th17/Treg decreased after treatment in both groups(P<0.05),and were lower in the treatment group than in the control group(P<0.05).The total effective rate was higher in the treatment group than in the control group(91.80%[56/61]vs 77.05%[47/61],P<0.05).There was no statistically significant difference in the incidence of adverse events between the two groups(P>0.752).Conclusion Shenfu Jiuxin Decoction shows significant efficacy in the treatment of CHF complicated by BA.It can improve cardiac function and ventricular remodeling,restore immune function,and has a favorable safety profile.

索新祺;张望;何锐;赵运;王旭;翟夏

陕西中医药大学第二附属医院心血管内科,陕西 咸阳 712000陕西中医药大学第二附属医院心血管内科,陕西 咸阳 712000陕西中医药大学第二附属医院心血管内科,陕西 咸阳 712000陕西中医药大学第二附属医院心血管内科,陕西 咸阳 712000陕西中医药大学第二附属医院心血管内科,陕西 咸阳 712000陕西中医药大学第二附属医院心血管内科,陕西 咸阳 712000

医药卫生

心力衰竭心律失常参附救心汤心室重构Th17细胞T淋巴细胞,调节性

Heart failureArrhythmiaShenfu Jiuxin DecoctionVentricular remodelingTh17 cellsRegulatory T cell

《河北中医》 2026 (9)

1454-1458,5

陕西省重点研发计划项目(编号:2023-YBSF-674)2023年省级公共卫生发展项目

10.3969/j.issn.1002-2619.2026.09.009

评论